CAR-T treatment characteristics and relapsed disease features after CAR-T
| Characteristic . | Total cohort (n = 96) . |
|---|---|
| CAR T-cell product administered, n (%) | |
| Axicabtagene ciloleucel | 51 (53.1) |
| Tisagenlecleucel | 25 (26.0) |
| Lisocabtagene maraleucel | 18 (18.8) |
| Other | 2 (2.1) |
| Receipt of any bridging therapy before CAR-T, n (%) | 66 (68.8) |
| Receipt of bridging radiation therapy before CAR-T, n (%) | 3 (3.1) |
| Response rates, n (%) | |
| ORR | 56 (58.3) |
| CR | 25 (26.0) |
| Median time to recurrence after CAR-T, d (range) | 84 (4-624) |
| Timing of relapse after CAR-T, n (%) | |
| Early relapse (≤180 d) | 80 (83.3) |
| Late relapse (>180 d) | 14 (14.6) |
| No relapse | 2 (2.1) |
| Clinical features at relapse after CAR-T | |
| ECOG PS, n (%) | |
| 0 | 22 (24.2) |
| 1 | 53 (58.2) |
| 2 | 11 (12.1) |
| 3 | 4 (4.4) |
| 4 | 1 (1.1) |
| Missing/unknown | 5 |
| Ann-Arbor Stage, n (%) | |
| I | 6 (6.3) |
| II | 18 (18.9) |
| III | 11 (11.6) |
| IV | 60 (63.2) |
| Missing/unknown | 1 |
| Extranodal disease, n (%) | |
| No | 23 (24.2) |
| Yes, only 1 site | 32 (33.7) |
| Yes, >1 site | 40 (42.1) |
| Missing/unknown | 1 |
| Bulky disease present, n (%) | 25 (26.0) |
| LDH > upper limit of normal, n (%) | 53 (55.2) |
| CNS involvement present at relapse, n (%) | 9 (9.4) |
| Characteristic . | Total cohort (n = 96) . |
|---|---|
| CAR T-cell product administered, n (%) | |
| Axicabtagene ciloleucel | 51 (53.1) |
| Tisagenlecleucel | 25 (26.0) |
| Lisocabtagene maraleucel | 18 (18.8) |
| Other | 2 (2.1) |
| Receipt of any bridging therapy before CAR-T, n (%) | 66 (68.8) |
| Receipt of bridging radiation therapy before CAR-T, n (%) | 3 (3.1) |
| Response rates, n (%) | |
| ORR | 56 (58.3) |
| CR | 25 (26.0) |
| Median time to recurrence after CAR-T, d (range) | 84 (4-624) |
| Timing of relapse after CAR-T, n (%) | |
| Early relapse (≤180 d) | 80 (83.3) |
| Late relapse (>180 d) | 14 (14.6) |
| No relapse | 2 (2.1) |
| Clinical features at relapse after CAR-T | |
| ECOG PS, n (%) | |
| 0 | 22 (24.2) |
| 1 | 53 (58.2) |
| 2 | 11 (12.1) |
| 3 | 4 (4.4) |
| 4 | 1 (1.1) |
| Missing/unknown | 5 |
| Ann-Arbor Stage, n (%) | |
| I | 6 (6.3) |
| II | 18 (18.9) |
| III | 11 (11.6) |
| IV | 60 (63.2) |
| Missing/unknown | 1 |
| Extranodal disease, n (%) | |
| No | 23 (24.2) |
| Yes, only 1 site | 32 (33.7) |
| Yes, >1 site | 40 (42.1) |
| Missing/unknown | 1 |
| Bulky disease present, n (%) | 25 (26.0) |
| LDH > upper limit of normal, n (%) | 53 (55.2) |
| CNS involvement present at relapse, n (%) | 9 (9.4) |